Evidence map›Paper›PMID 35677637›Full record

ArticleDisease markers2022

Mining the Prognostic Role of DNA Methylation Heterogeneity in Lung Adenocarcinoma.

Hongying Liao, Xiaolong Luo, Yisheng Huang, Xingping Yang, Yuzhen Zheng, Xianyu Qin, Jian Tan, Piao Shen, Renjiang Tian, Weijie Cai and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Disease markers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Hongying LiaoDepartment of Thoracic Surgery, Thoracic Cancer Center, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.ORCID https://orcid.org/0000-0002-9771-5680
Xiaolong LuoDepartment of Thoracic Surgery, Zhanjiang Central People's Hospital, Chikan District, Zhanjiang City, Guangdong Province, China.ORCID https://orcid.org/0000-0001-9894-7339
Yisheng HuangDepartment of Oncology, Maoming People's Hospital, Maoming, China.ORCID https://orcid.org/0000-0002-3949-5405
Xingping YangDepartment of Thoracic Surgery, Thoracic Cancer Center, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.ORCID https://orcid.org/0000-0002-4476-266X
Yuzhen ZhengDepartment of Thoracic Surgery, Thoracic Cancer Center, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.ORCID https://orcid.org/0000-0002-5260-6798
Xianyu QinDepartment of Thoracic Surgery, Thoracic Cancer Center, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.ORCID https://orcid.org/0000-0001-6891-7614
Jian TanDepartment of Thoracic Surgery, Thoracic Cancer Center, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.ORCID https://orcid.org/0000-0002-7852-9815
Piao ShenDepartment of Thoracic Surgery, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.ORCID https://orcid.org/0000-0002-2158-600X
Renjiang TianDepartment of Thoracic Surgery, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.ORCID https://orcid.org/0000-0001-6928-4855
Weijie CaiDepartment of Thoracic Surgery, Thoracic Cancer Center, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.ORCID https://orcid.org/0000-0003-2818-6057
Xiaoshun ShiDepartment of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.ORCID https://orcid.org/0000-0003-3467-6386
Xiaofang DengDepartment of Internal Medicine, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou Key Laboratory of Translational Medicine on Malignant Tumor Treatment, Guangzhou, China.ORCID https://orcid.org/0000-0002-8049-077X
Sun Yat-sen University · CNGuangzhou Medical University · CNCentral People's Hospital of Zhanjiang · CNNanfang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: DNA methylation heterogeneity is a type of tumor heterogeneity in the tumor microenvironment, but studies on the identification of the molecular heterogeneity of the lung adenocarcinoma genome with respect to DNA methylation sites and their roles in lung cancer progression and prognosis are scarce. Methods: Prognosis-associated DNA methylation subtypes were filtered by the Cox proportional hazards model and then established by unsupervised cluster analysis. Association analysis of these subtypes with clinical features and functional analysis of annotated genes potentially affected by methylation sites were performed. The robustness of the model was further tested by a Bayesian network classifier. Results: Over 7 thousand methylation sites were associated with lung adenocarcinoma prognosis. We identified seven molecular methylation subtypes, including 630 methylation sites. The subtypes yielded the most stable results for differentiating methylation profiles, prognosis, and gene expression patterns. The annotated genes potentially affected by these methylation sites are enriched in biological processes such as morphogenesis and cell adhesion, but their individual impact on the tumor microenvironment and prognosis is multifaceted.

Indexed as

Adenocarcinoma of LungLung NeoplasmsBayes TheoremBiomarkers, TumorDNA MethylationGene Expression Regulation, NeoplasticHumansPrognosisTumor MicroenvironmentBiomarkers, Tumor

Identifiers

PMID35677637
PMCPMC9168807
OpenAlexW4281745858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.